Revenue (Quarterly) Chart

View Revenue (Quarterly) for EPGNF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2023 0.0762M
March 31, 2023 0.1438M
December 31, 2022 0.101M
September 30, 2022 0.146M
June 30, 2022 0.1341M
March 31, 2022 0.129M
December 31, 2021 0.2069M
September 30, 2021 6.835M
June 30, 2021 0.1411M
March 31, 2021 0.1277M
December 31, 2020 0.3588M
September 30, 2020 0.256M
June 30, 2020 0.0914M
March 31, 2020 0.2633M
December 31, 2019 0.3078M
September 30, 2019 0.1868M
June 30, 2019 0.391M
March 31, 2019 0.3758M
December 31, 2018 0.2488M
September 30, 2018 0.6327M
June 30, 2018 0.5502M
March 31, 2018 0.3798M
December 31, 2017 1.166M
September 30, 2017 0.4064M
June 30, 2017 0.2709M
Date Value
March 31, 2017 0.2995M
December 31, 2016 1.919M
September 30, 2016 0.9643M
June 30, 2016 1.423M
March 31, 2016 0.3252M
December 31, 2015 0.8296M
September 30, 2015 0.5235M
June 30, 2015 0.5387M
March 31, 2015 0.4126M
December 31, 2014 0.5146M
September 30, 2014 0.3763M
June 30, 2014 0.5554M
March 31, 2014 0.5577M
December 31, 2013 0.8535M
September 30, 2013 0.3483M
June 30, 2013 0.4478M
March 31, 2013 0.4687M
December 31, 2012 0.476M
September 30, 2012 0.3401M
June 30, 2012 0.20M
March 31, 2012 0.3185M
December 31, 2011 0.2627M
September 30, 2011 0.3627M
June 30, 2011 0.5238M
March 31, 2011 0.8498M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
CureVac NV 63.26M
PAION AG --
Anbio Biotechnology --
Anika Therapeutics, Inc. 32.61M
Perspective Therapeutics, Inc. 0.081M

Revenue (Quarterly) Related Metrics